Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.37 |
| ▸ | DAO | P14920 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | PKLR | P30613 | 1/20 | 0.37 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | MPI | P34949 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23064539 | 0.82 | ALDH1A1 (0.48) | KMT2AALDH1A1MAPTCYP2A13KDM4E | |
| SCHEMBL30079434 | 0.79 | ALDH1A1 (0.43) | PDE7AKMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL21447982 | 0.77 | DRD2 (0.54) | ALDH1A1HTR1A | |
| SCHEMBL1375448 | 0.77 | CYP2A13 (0.37) | PDE7AKMT2AALDH1A1MAPTNOTUM | |
| SCHEMBL30241928 | 0.76 | ALDH1A1 (0.40) | KMT2AALDH1A1MAPTNOTUMPKM | |
| SCHEMBL17543702 | 0.76 | KMT2A (0.38) | KMT2AALDH1A1MAPTMEN1L3MBTL1 | |
| SCHEMBL30079590 | 0.75 | HTR3E (0.47) | KMT2ANOTUMC5AR1MEN1 | |
| SCHEMBL30079381 | 0.74 | L3MBTL1 (0.40) | KMT2AALDH1A1MAPTKDM4EC5AR1 | |
| SCHEMBL17543135 | 0.73 | KMT2A (0.41) | KMT2AALDH1A1 | |
| SCHEMBL17542732 | 0.72 | SMN1; SMN2 (0.40) | KMT2AALDH1A1CYP2A13KDM4EHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106795117-B | Heterobicyclic compounds and their use for the treatment of tuberculosis | 大塚制药株式会社 | 2020-06-26 | — | — | CN | disclosed |
| US-10464926-B2 | Heterobicyclic compounds and their use for the treatment of tuberculosis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-11-05 | — | — | US | disclosed |
| EP-3186240-B1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2019-06-12 | — | — | EP | disclosed |
| US-20180312488-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-11-01 | — | — | US | disclosed |
| US-10053446-B2 | Heterobicyclic compounds and their use for the treatment of tuberculosis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-08-21 | — | — | US | disclosed |
| US-20170253576-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-09-07 | — | — | US | disclosed |
| EP-3186240-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2017-07-05 | — | — | EP | disclosed |
| WO-2016031255-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10053446-B2 | Heterobicyclic compounds and their use for the treatment of tuberculosis | FNTB, SLC11A2, TBCD | PDE7A 3471/4885KMT2A 2525/4885ALDH1A1 1458/4885 |
| US-10464926-B2 | Heterobicyclic compounds and their use for the treatment of tuberculosis | FNTB, SLC11A2, TBCD | PDE7A 3471/4885KMT2A 2525/4885ALDH1A1 1458/4885 |
| US-20180312488-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | FNTB, SLC11A2, TBCD | PDE7A 3471/4885KMT2A 2525/4885ALDH1A1 1458/4885 |
| US-20170253576-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | FNTB, SLC11A2, TBCD | PDE7A 3471/4885KMT2A 2525/4885ALDH1A1 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.